ArticleTargeted oncology2019

Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.

Anna W Chalmers et al.PubMed ↗Publisher ↗

No numbers read from the abstract.